Elnachef Najwa, McMorris Marc, Chey William D
Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan 48109-0362, USA.
Am J Gastroenterol. 2007 Jun;102(6):1322-5. doi: 10.1111/j.1572-0241.2007.01141.x.
Common variable immunodeficiency disorder (CVID) is an immunological disease that can present with gastrointestinal (GI) symptoms including chronic diarrhea and abdominal pain. We report a patient with CVID and chronic diarrhea who significantly improved with budesonide.
A 47-yr-old woman with CVID-associated diarrhea, steatorrhea, abdominal pain, and bloating for several years had an exhaustive evaluation for secondary causes of her symptoms, which was unrevealing. At the advice of her immunologist, she attempted a course with budesonide that significantly improved her GI symptoms. Given the absence of literature on this treatment in CVID, we attempted to systematically evaluate the clinical benefits after withdrawal of and retreatment with budesonide.
Diarrhea, steatorrhea, abdominal pain, and bloating recurred within 2 days of discontinuing budesonide. All parameters assessed improved upon reinitiating budesonide. Further, serum immunoglobulin G (IgG) levels significantly increased with treatment. No significant side effects were observed with budesonide.
This is the first report of a patient with CVID-related chronic diarrhea to be successfully treated with oral budesonide. This observation provides clinicians with an effective and safe treatment option in this difficult group of patients.
普通可变免疫缺陷病(CVID)是一种可出现包括慢性腹泻和腹痛在内的胃肠道(GI)症状的免疫性疾病。我们报告一例患有CVID和慢性腹泻的患者,其使用布地奈德后症状显著改善。
一名47岁女性患有与CVID相关的腹泻、脂肪泻、腹痛和腹胀数年,对其症状的继发原因进行了详尽评估,但未发现异常。在其免疫学家的建议下,她尝试使用布地奈德治疗,结果其胃肠道症状显著改善。鉴于CVID中关于该治疗方法的文献较少,我们试图系统评估停用布地奈德及再次用药后的临床获益情况。
停用布地奈德后2天内,腹泻、脂肪泻、腹痛和腹胀复发。重新使用布地奈德后,所有评估参数均有所改善。此外,治疗后血清免疫球蛋白G(IgG)水平显著升高。使用布地奈德未观察到明显副作用。
这是首例关于使用口服布地奈德成功治疗CVID相关慢性腹泻患者的报告。该观察结果为临床医生为这类难治性患者提供了一种有效且安全的治疗选择。